Abdulredha Esmail
Research Interests
Abdulredha Esmail has a total of 29 co-authors. Here are the top co-authors by number of shared publications:
- Akram Al-Ibraheem
Department of Nuclear Medicine, King Hussein Cancer Center (KHCC), Amman 11941, Jordan
3 shared publications - Abdullah Alqarni
Nuclear Medicine Department, Prince Sultan Medical Military City, Riyadh, Saudi Arabia
2 shared publications - Ahmed Saad Abdlkadir
Department of Nuclear Medicine, King Hussein Cancer Center (KHCC), Amman, Jordan
2 shared publications - Aysar Khalaf
Department of Nuclear Medicine, Warith International Cancer Institute, Karbala, Iraq
2 shared publications - Batool Albalooshi
Dubai Nuclear Medicine and Molecular Imaging Center, Dubai Health Authority, Dubai, UAE
2 shared publications - Dyab Al Mahariq
Department of Radiology, Augusta Victoria Hospital, Jerusalem, Palestine
2 shared publications
Latest Publications
- Open Access
- 21 May 2025
- Published by Springer Nature in Nuclear Medicine and Molecular Imaging
- Vol. 59 (6) , 484-485
Correction to: Current Status of Theranostics in West Asia: A Country-based Surveillance Study
- 21 May 2025
- Published by Springer Nature in Nuclear Medicine and Molecular Imaging
- Vol. 59 (6) , 484-485
Open AccessCorrection to: Current Status of Theranostics in West Asia: A Country-based Surveillance Study
- 20 March 2025
- Published by Springer Nature in Nuclear Medicine and Molecular Imaging
- Vol. 59 (5) , 1-9
Current Status of Theranostics in West Asia: A Country-based Surveillance Study
This surveillance study examined the status of theranostics in West Asia, analyzing data from 15 countries. The research assessed availability, production, coverage, staff density, infrastructure density, financial and political impacts. All surveyed countries except Yemen offered theranostic services, with 452 centers and 1,426 theranostic physicians across the region. Over half of the countries reported densities exceeding one theranostician, nuclear medicine technologist, physicist, and nurse per million inhabitants. Scientific and social activities were available in nine and ten countries, respectively. Countries with gross domestic product (GDP) below $200 billion showed significantly lower infrastructure and manpower resources, particularly in cyclotron availability and theranostic agents (p < 0.05), compared to those with higher GDP. Politically stable countries demonstrated statistically higher densities of theranostic personnel than unstable nations (p < 0.05). The study emphasizes the importance of collaboration between model countries and those lacking adequate services to enhance theranostic practice and availability in West Asia.
- 20 March 2025
- Published by Springer Nature in Nuclear Medicine and Molecular Imaging
- Vol. 59 (5) , 1-9
Current Status of Theranostics in West Asia: A Country-based Surveillance Study
This surveillance study examined the status of theranostics in West Asia, analyzing data from 15 countries. The research assessed availability, production, coverage, staff density, infrastructure density, financial and political impacts. All surveyed countries except Yemen offered theranostic services, with 452 centers and 1,426 theranostic physicians across the region. Over half of the countries reported densities exceeding one theranostician, nuclear medicine technologist, physicist, and nurse per million inhabitants. Scientific and social activities were available in nine and ten countries, respectively. Countries with gross domestic product (GDP) below $200 billion showed significantly lower infrastructure and manpower resources, particularly in cyclotron availability and theranostic agents (p < 0.05), compared to those with higher GDP. Politically stable countries demonstrated statistically higher densities of theranostic personnel than unstable nations (p < 0.05). The study emphasizes the importance of collaboration between model countries and those lacking adequate services to enhance theranostic practice and availability in West Asia.
- Open Access
- 6 October 2023
- Published by Springer Nature in Research Square
Initial Clinical Experience using 68Ga-FAPI-46 PET/CT for Detecting Various Cancer Types
Purpose Numerous studies have demonstrated that 68Ga-FAPI PET/CT scans would yield high intra-tumoral tracer uptake and low uptake in normal tissues as background, thus allowing for excellent visualization of lesions in the cancer microenvironment. This study set out to compare the suitability of 68Ga-FAPI-46 PET versus routine 18F-FDG PET, 68Ga-DOTATATE and 68Ga-Pentixafor radiotracers for the assessment of different types of cancer. Methods A retrospective analysis of 11 patients (6 males, 5 females; mean age: 53 years, range: 10–58 years) with histopathologically confirmed, well-differentiated adenocarcinoma, medullar thyroid cancer (MTC), papillary thyroid carcinoma (PTC), cervical, gastric, glioblastoma multiform (GBM), colon, Ewing's sarcoma, and breast cancer was performed. These patients underwent PET/CT scans using four different radiotracers (9 18F-FDG, 11 68Ga-FAPI, 3 68Ga-DOTATATE, and 1 68Ga-Pentixafor). The patients' PET/CT images were visually evaluated for cancer detection, and analyzed semi-quantitatively through image-derived metrics, such as target-to-background ratio (TBR) and maximum standard uptake value (SUVmax), for recurrence and metastasis. Results The study of 11 patients revealed that 68Ga-FAPI-46 was more effective than other tracers for detecting metastases, with 55 vs. 49 metastases in the lymph nodes, 4 vs. 3 in the liver, and 4 vs. 3 in the bones detected in comparison to 18F-FDG. No significant differences were observed in 68Ga-DOTATATE and 68Ga-Pentixafor PET images (P-value > 0.05). In addition, in five patients, the SUVmax and TBR values in 68Ga-FAPI-46 PET images were significantly higher than 18F-FDG PET images for lymph nodes and bone metastases. Although the SUVmax in 68Ga-FAPI-46 and 18F-FDG PET images for liver metastases was comparable, 68Ga-FAPI-46 had a significantly higher TBR than 18F-FDG. Conclusions 68Ga-FAPI-46 PET images led to improved detection rates for most metastases and better patient classification compared to 18F-FDG, 68Ga-Pentixafor, and 68Ga-DOTATATE. However, 18F-FDG PET/CT detected more lymph nodes than 68Ga-FAPI-46 PET/CT in various types of cancer.
- 6 October 2023
- Published by Springer Nature in Research Square
Open AccessInitial Clinical Experience using 68Ga-FAPI-46 PET/CT for Detecting Various Cancer Types
Purpose Numerous studies have demonstrated that 68Ga-FAPI PET/CT scans would yield high intra-tumoral tracer uptake and low uptake in normal tissues as background, thus allowing for excellent visualization of lesions in the cancer microenvironment. This study set out to compare the suitability of 68Ga-FAPI-46 PET versus routine 18F-FDG PET, 68Ga-DOTATATE and 68Ga-Pentixafor radiotracers for the assessment of different types of cancer. Methods A retrospective analysis of 11 patients (6 males, 5 females; mean age: 53 years, range: 10–58 years) with histopathologically confirmed, well-differentiated adenocarcinoma, medullar thyroid cancer (MTC), papillary thyroid carcinoma (PTC), cervical, gastric, glioblastoma multiform (GBM), colon, Ewing's sarcoma, and breast cancer was performed. These patients underwent PET/CT scans using four different radiotracers (9 18F-FDG, 11 68Ga-FAPI, 3 68Ga-DOTATATE, and 1 68Ga-Pentixafor). The patients' PET/CT images were visually evaluated for cancer detection, and analyzed semi-quantitatively through image-derived metrics, such as target-to-background ratio (TBR) and maximum standard uptake value (SUVmax), for recurrence and metastasis. Results The study of 11 patients revealed that 68Ga-FAPI-46 was more effective than other tracers for detecting metastases, with 55 vs. 49 metastases in the lymph nodes, 4 vs. 3 in the liver, and 4 vs. 3 in the bones detected in comparison to 18F-FDG. No significant differences were observed in 68Ga-DOTATATE and 68Ga-Pentixafor PET images (P-value > 0.05). In addition, in five patients, the SUVmax and TBR values in 68Ga-FAPI-46 PET images were significantly higher than 18F-FDG PET images for lymph nodes and bone metastases. Although the SUVmax in 68Ga-FAPI-46 and 18F-FDG PET images for liver metastases was comparable, 68Ga-FAPI-46 had a significantly higher TBR than 18F-FDG. Conclusions 68Ga-FAPI-46 PET images led to improved detection rates for most metastases and better patient classification compared to 18F-FDG, 68Ga-Pentixafor, and 68Ga-DOTATATE. However, 18F-FDG PET/CT detected more lymph nodes than 68Ga-FAPI-46 PET/CT in various types of cancer.